Skip to main content

Table 4 Serious adverse events

From: Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]

Adverse event

Control

Group A

Group B

Deaths

7

5

10

Nosocomial infection

21

22

26

Heart rate and rhythm disorders

3

2

2

Thrombocytosis

1

-

1

Deep vein thrombosis

2

-

1

Central nervous system disorders (new ischaemic or haemorrhagic stroke)

3

2

2